As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

In their June 5 report, DBS Group Research analysts Foo Fang Boo and Ling Lee Keng point to the strong year-to-date (ytd) ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...